Gilteritinib

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Adult Indications and Dosage

Plasma Concentration

  • After 15 days, the plasma concentration becomes steady
    • Maximum Concentration: 374 ng/mL
    • AUC: 6943 ng.h/mL
  • The Data is different in people who are fasting
    • The Maximum Concentration decreased by 26%
    • AUC decreased by 10%

Excretion

  • About 64.5% of the administered dose is excreted in the feces
  • About 16.4% of the administered dose goes through the urine

Distribution

  • Central Volume of Distribution is approximately 1092 L
  • Peripheral Volume of Distribution is approximately 1100 L

Pediatric Indications and Dosage

Contradictions

Warnings

Adverse Reactions

Differentiation Syndrome

  • May result in some "life-threatening symptoms" known as differentiation syndrome
    • Contact doctor immediately if any of these symptoms occur:
    • Fever, cough rash, rapid weight gain, vertigo, urination problems, joint swelling, difficulty breathing, chest pain, or joint pain

Side Effects

  • If persists, call a doctor:
    • joint/muscle pain, severe tiredness, acute vomiting and nausea, diarrhea, mouth sores, loss in taste/ appetite, headache or insomnia
  • More Serious
    • Seizures, difference in heartbeat, persisting pain in the abdomen region that could spread to the back

Drug Interactions

Use in Specific Populations

Administration and Monitoring

IV Compatibility

Overdosage

Pharmacology

Clinical Studies

How is it Supplied

Patient Counseling Information

Precautions with Alcohol

Brand Names

  • Xospata

Names of Drugs that Look Alike

Drug Shortage Status

Price

Contraindicated Medications

{{MedCondContrAbs |MedCond = NameOfTheContraindication|Drug1|Drug2|Drug3}}